Kasabach Merritt syndrome is a rare disease consisting of a vascular tumor (kaposiform hemangioendothelioma, tufted or congenital angioma), thrombocytopenia and consumptive coagulopathy (hypofibrinogenemia). When microangiopathic hemolytic anemia is also present, the condition is called Kasabach Merritt phenomenon. This pathology has a lethal potential, due to its natural evolution to disseminated intravascular coagulopathy.
Presentation
Patients with Kasabach Merritt syndrome may present for the evaluation of cutaneous lesions [1], for symptoms caused by visceral vascular tumors or for milder dermal manifestations of the disease [2], like petechiae, bruising [3] or bleeding. With hepatic angiomas, patients can have hepatomegaly and jaundice. If the vascular tumor is large, a great amount of blood circulates within it, causing symptomatic high output heart failure [4]. Large lesions may also cause compression of the neighboring structures, with various signs, depending on their location. Death can be due to cerebral bleeding from an intracranial pathology [5], or secondary to disseminated intravascular coagulation, multiorgan failure, shock, and sepsis. Hemangiomas may be located anywhere: the skin, retroperitoneal organs, mediastinum, pelvis, neck, limbs, musculoskeletal, visceral organs. Symptoms may become worse as the child grows older and subsequently, the vascular tumor grows larger. However, patients may remain asymptomatic until they become adults or may present during the first weeks of life.
When no cutaneous lesions are present, the diagnosis is easily missed unless a thorough examination that suggests liver or spleen enlargement, for instance, is performed [6]. Still, clinical examination may be uninformative in some patients, like those with intraosseous disease [7] [8], therefore the diagnosis relies on a high level of suspicion, laboratory and imaging data.
Workup
Clinical examination may reveal pallor, reddish-brown, indurated lesions [9], classical capillary hemangiomas or tufted angiomas. Patients may be tachycardic due to the anemia, heart failure or shock. Lesion ulceration and infection are rarely seen.
In Kasabach Merritt syndrome, blood workup should include complete blood count, peripheral smear, fibrinogen, fibrin degradation products, D-dimers, prothrombin time and activated partial thromboplastin time. The laboratory personnel should look for Burr cells and schistocytes. Disseminated intravascular coagulation is accompanied by prolonged prothrombin time and activated partial thromboplastin time, low fibrinogen level, elevated fibrin degradation product and D-dimer levels. Intravascular coagulation may also have a chronic, low-grade character.
It is important to determine the extent of cutaneous lesions and the existence of other involved sites, therefore radiography, ultrasonography- especially Doppler flow, computed tomography, Indium or Chromium radionuclide scintigraphy [10] magnetic resonance imaging scans and angiographic scans should be performed. Angiography can be followed by embolization. When the nature of the tumor is uncertain, histologic findings are important to evaluate its nature [11], but biopsies are usually not performed due to the critical state of the patient unless surgical procedures are performed with curative intent. Most frequently, kaposiform haemangioendothelioma and tufted angiomas are found [12]. Both contain dilated capillary vessels with endothelial lesions, microthrombi, lymphlike vessels and hemosiderin deposits, and both may be found in the same patient.
Treatment
Treatment of Kasabach-Merritt Syndrome focuses on managing the vascular tumor and correcting the associated hematological abnormalities. Options may include corticosteroids, which help reduce inflammation and tumor size, and other medications like vincristine or sirolimus, which target the tumor's growth. In some cases, surgical removal of the tumor or interventional radiology techniques, such as embolization, may be necessary. Supportive care, including platelet transfusions, may be required to manage bleeding complications.
Prognosis
The prognosis for Kasabach-Merritt Syndrome varies depending on the size and location of the tumor, the severity of the hematological abnormalities, and the response to treatment. With appropriate management, many patients experience significant improvement. However, the condition can be life-threatening if not promptly and effectively treated, particularly due to the risk of severe bleeding.
Etiology
The exact cause of Kasabach-Merritt Syndrome is not well understood. It is associated with specific types of vascular tumors, such as kaposiform hemangioendothelioma and tufted angioma, which are thought to arise from abnormal development of blood vessels. The syndrome is not inherited and typically occurs sporadically.
Epidemiology
Kasabach-Merritt Syndrome is a rare condition, with only a limited number of cases reported in the medical literature. It primarily affects infants and young children, with no significant gender predilection. Due to its rarity, the exact incidence and prevalence are not well established.
Pathophysiology
The pathophysiology of Kasabach-Merritt Syndrome involves the interplay between the vascular tumor and the body's clotting system. The tumor traps and destroys platelets, leading to thrombocytopenia. Additionally, the tumor may consume clotting factors, resulting in a coagulopathy (a disorder of blood clotting). This combination of factors leads to an increased risk of bleeding.
Prevention
Currently, there are no known measures to prevent Kasabach-Merritt Syndrome, as its exact cause is not well understood. Early recognition and treatment of the condition are crucial to prevent complications and improve outcomes.
Summary
Kasabach-Merritt Syndrome is a rare and serious condition characterized by a vascular tumor, low platelet count, and bleeding tendency. It primarily affects infants and young children and requires prompt diagnosis and treatment to manage the tumor and associated hematological abnormalities. While the exact cause is unknown, effective treatment options are available, and the prognosis can be favorable with appropriate management.
Patient Information
Kasabach-Merritt Syndrome is a rare condition that affects young children, involving a type of tumor made up of blood vessels. This tumor can cause problems with blood clotting, leading to a low number of platelets and an increased risk of bleeding. Symptoms may include a noticeable lump on the skin, bruising, or bleeding. Treatment often involves medications to shrink the tumor and manage bleeding risks. With proper care, many children improve significantly, but early diagnosis and treatment are important.
References
- Arunachalam P, Kumar VR, Swathi D. Kasabach-Merritt syndrome with large cutaneous vascular tumors. J Indian Assoc Pediatr Surg. 2012;17(1):33-6
- Sidbury R. Update on vascular tumors of infancy. Curr Opin Pediatr. 2010;22:432–437.
- Tang JY, Chen J, Pan C, et al. Diffuse cavernous hemangioma of the spleen with Kasabach-Merritt syndrome misdiagnosed as idiopathic thrombocytopenia in a child. World J Pediatr. 2008;4(3):227-230.
- Enjolras O, Riche MC, Merland JJ, et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990;85(4):491-498.
- Maguiness S, Guenther L. Kasabach-Merritt syndrome. J Cutan Med Surg. 2002;6:335–9.
- Von Schweinitz D, Gluer S, Mildenberger H. Liver tumors in neonates and very young infants: diagnostic pitfalls and therapeutic problems. Eur J Ped Surg. 1995; 5:72–76.
- Biswal BM, Anand AK, Aggarwal HN, et al. Vertebral haemangioma presenting as Kasabach–Merritt syndrome. Clinical Oncology. 1993;5:187–188.
- Carrington PR, Rowley MJ, Fowler M, et al. Kasabach–Merritt syndrome with bone involvement: the pseudomalignant sign of Gorham. J Am Acad Dermatol. 1993; 29:117–119.
- Mitsuhashi N, Furuta M, Sakurai H, et al. Outcome of radiation therapy for patients with Kasabach-Merritt syndrome. Int J Radiat Oncol Biol Phys. 1997; 39(2):467-473.
- Pampin C, Devillers A, Treguier C, et al. Intratumoral consumption of indium-111-labeled platelets in a child with splenic hemangioma and thrombocytopenia. J Pediatr Hematol Oncol. 2000;22(3):256-258.
- Mueller BU, Mulliken JB. The infant with a vascular tumor. Seminars in Perinatology. 1999;23:332–340.
- Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach–Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstruct Surg. 1997;100:1377–1386.